These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 14752066

  • 1. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B.
    J Clin Oncol; 2004 Feb 01; 22(3):424-31. PubMed ID: 14752066
    [Abstract] [Full Text] [Related]

  • 2. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM.
    Cancer; 2006 May 01; 106(9):1974-84. PubMed ID: 16583431
    [Abstract] [Full Text] [Related]

  • 3. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G, Marchetti M, Pozzato G, Zorat F, Tefferi A.
    Leuk Lymphoma; 2002 Dec 01; 43(12):2301-7. PubMed ID: 12613516
    [Abstract] [Full Text] [Related]

  • 4. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
    Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM, Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS).
    Haematologica; 2006 Aug 01; 91(8):1027-32. PubMed ID: 16885042
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
    Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A, Malagola M, Finelli C, Martinelli G, Ricci P, Baccarani M, Tura S.
    Leukemia; 2002 Sep 01; 16(9):1609-14. PubMed ID: 12200671
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thalidomide for the treatment of idiopathic myelofibrosis.
    Strupp C, Germing U, Scherer A, Kündgen A, Mödder U, Gattermann N, Haas R.
    Eur J Haematol; 2004 Jan 01; 72(1):52-7. PubMed ID: 14962263
    [Abstract] [Full Text] [Related]

  • 8. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA, Elliott MA, Schroeder G, Tefferi A.
    Mayo Clin Proc; 2004 Jul 01; 79(7):883-9. PubMed ID: 15244384
    [Abstract] [Full Text] [Related]

  • 9. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
    Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A.
    Leukemia; 2011 Feb 01; 25(2):301-4. PubMed ID: 21052089
    [Abstract] [Full Text] [Related]

  • 10. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J, Maisnar V.
    Vnitr Lek; 2007 Feb 01; 53(2):129-34. PubMed ID: 17419173
    [Abstract] [Full Text] [Related]

  • 11. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR.
    Am J Med; 2005 Mar 01; 118(3):246-50. PubMed ID: 15745722
    [Abstract] [Full Text] [Related]

  • 12. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A.
    Blood; 2003 Apr 01; 101(7):2534-41. PubMed ID: 12517815
    [Abstract] [Full Text] [Related]

  • 13. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M, Zhou D.
    Hematology; 2019 Dec 01; 24(1):516-520. PubMed ID: 31242816
    [Abstract] [Full Text] [Related]

  • 14. Low-dose thalidomide in myelofibrosis.
    Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN.
    Haematologica; 2008 Jul 01; 93(7):1100-1. PubMed ID: 18508796
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
    Faoro LN, Tefferi A, Mesa RA.
    Eur J Haematol; 2005 Feb 01; 74(2):117-20. PubMed ID: 15654901
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.